Jaguar Health, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $5.830 million for the third quarter and a swing from stockholders' deficit to positive stockholders' equity.
Key Highlights
- Net loss narrowed: Jaguar Health reported a net loss of $5.830 million for the three months ended September 30, 2026, compared to a net loss of $9.648 million for the same period in 2025, according to the filing.
- Nine-month net loss: For the nine months ended September 30, 2026, the company reported a net loss of $9.909 million, versus $30.804 million for the same period in 2025.
- License revenue surged: Nine-month license revenue reached $20.878 million for 2026, compared to $128 thousand in the same period of 2025.
- Stockholders' equity turned positive: Total stockholders' equity was $18.623 million as of September 30, 2026, compared to a deficit of $18.688 million as of December 31, 2025.
- Accumulated deficit: The accumulated deficit stood at $409.463 million as of September 30, 2026, up from $399.916 million at December 31, 2025.
- Notes payable declined sharply: Current notes payable, net of discount, fell to $2.493 million as of September 30, 2026, from $27.440 million as of December 31, 2025.
- Shares outstanding: As of November 13, 2026, there were 13,345,986 shares of voting common stock outstanding, with 0 shares of non-voting common stock outstanding.
Jaguar Health Reports Sharply Lower Nine-Month Loss and Balance Sheet Restructuring
Jaguar Health, Inc. (NASDAQ:JAGX), a Delaware-incorporated company headquartered at 200 Pine Street, Suite 400, San Francisco, California, filed its quarterly report covering the period ended September 30, 2026. The filing shows total revenue, net, of $2.343 million for the three months ended September 30, 2026, compared to $3.083 million in the same quarter of 2025. For the nine months ended September 30, 2026, total revenue, net, was $23.840 million versus $8.276 million for the comparable prior-year period, according to the filing.
The company disclosed that license revenue was the primary driver of the nine-month increase, reaching $20.878 million for the nine months ended September 30, 2026, against $128 thousand in the same period of 2025. Product revenue, net, declined to $2.937 million for the nine-month period in 2026 from $8.148 million in 2025. Total operating expenses for the nine months ended September 30, 2026 were $27.278 million, down from $32.942 million in the prior-year period. The loss from operations for the nine months ended September 30, 2026 was $3.438 million, compared to $24.666 million for the same period in 2025.
The balance sheet shows a significant reduction in debt. The filing reports current notes payable, net of discount, of $2.493 million as of September 30, 2026, which includes notes designated at Fair Value Option of $2.2 million, compared to current notes payable of $27.440 million as of December 31, 2025, which included $26.2 million at Fair Value Option. All non-current notes payable were eliminated by September 30, 2026, compared to $15.083 million at December 31, 2025. Total liabilities were $13.888 million as of September 30, 2026, down from $57.011 million at December 31, 2025. Cash increased to $5.528 million from $968 thousand over the same period, while restricted cash declined from $6.864 million to zero.
What Was Disclosed
Jaguar Health's 10-Q for the quarter ended September 30, 2026, disclosed a narrower net loss compared to the prior year, a substantial increase in license revenue, a sharp reduction in notes payable, and a shift from negative to positive total stockholders' equity of $18.623 million.




Please wait processing your request...